Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Clinical and Experimental Rheumatology
|
September 29, 2015
Functionally active NKG2A-expressing natural killer cells are elevated in rheumatoid arthritis patients compared to psoriatic arthritis patients and healthy donors
S T A van Bijnen, M Cossu, M W H Roeven, et al.
Annals of the Rheumatic Diseases
|
November 19, 2008
Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis
B J Radovits, W Kievit, J Fransen, et al.
Annals of the Rheumatic Diseases
|
October 20, 2010
Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
E E A Arts, T L Jansen, A Den Broeder, et al.
Arthritis Care & Research
|
May 28, 2010
Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice
M Blom, W Kievit, H H Kuper, et al.
Scandinavian Journal of Rheumatology
|
March 19, 2013
Can response duration after the first rituximab treatment be used in timing of rituximab retreatment?
N van Herwaarden, A van der Maas, T L Jansen, et al.
Annals of the Rheumatic Diseases
|
January 25, 2011
EULAR recommendations for calcium pyrophosphate deposition. Part II: management
W Zhang, M Doherty, E Pascual, et al.
Annals of the Rheumatic Diseases
|
January 11, 2011
European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis
W Zhang, M Doherty, T Bardin, et al.
Annals of the Rheumatic Diseases
|
July 16, 2008
Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies
W Kievit, J Fransen, E M Adang, et al.
Annals of the Rheumatic Diseases
|
January 5, 2008
The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data
W Kievit, E M Adang, J Fransen, et al.
Annals of the Rheumatic Diseases
|
July 27, 2016
2016 updated EULAR evidence-based recommendations for the management of gout
P Richette, M Doherty, E Pascual, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Clinical and Experimental Rheumatology
|
September 29, 2015
Functionally active NKG2A-expressing natural killer cells are elevated in rheumatoid arthritis patients compared to psoriatic arthritis patients and healthy donors
S T A van Bijnen, M Cossu, M W H Roeven, et al.
Annals of the Rheumatic Diseases
|
November 19, 2008
Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis
B J Radovits, W Kievit, J Fransen, et al.
Annals of the Rheumatic Diseases
|
October 20, 2010
Statins inhibit the antirheumatic effects of rituximab in rheumatoid arthritis: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
E E A Arts, T L Jansen, A Den Broeder, et al.
Arthritis Care & Research
|
May 28, 2010
Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice
M Blom, W Kievit, H H Kuper, et al.
Scandinavian Journal of Rheumatology
|
March 19, 2013
Can response duration after the first rituximab treatment be used in timing of rituximab retreatment?
N van Herwaarden, A van der Maas, T L Jansen, et al.
Annals of the Rheumatic Diseases
|
January 25, 2011
EULAR recommendations for calcium pyrophosphate deposition. Part II: management
W Zhang, M Doherty, E Pascual, et al.
Annals of the Rheumatic Diseases
|
January 11, 2011
European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis
W Zhang, M Doherty, T Bardin, et al.
Annals of the Rheumatic Diseases
|
July 16, 2008
Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies
W Kievit, J Fransen, E M Adang, et al.
Annals of the Rheumatic Diseases
|
January 5, 2008
The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data
W Kievit, E M Adang, J Fransen, et al.
Annals of the Rheumatic Diseases
|
July 27, 2016
2016 updated EULAR evidence-based recommendations for the management of gout
P Richette, M Doherty, E Pascual, et al.
Page
of 7